Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes

Tyrosine kinase inhibitors (TKIs) have significantly changed the treatment of chronic myeloid leukemia (CML) and improved outcomes for patients with CML in chronic phase (CML-CP) and accelerated phase (AP). Now armed with numerous effective therapeutic options, clinicians must consider various patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Hijiya, Nobuko, Mauro, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460573/
https://www.ncbi.nlm.nih.gov/pubmed/37641687
http://dx.doi.org/10.2147/CMAR.S353374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460573/
https://www.ncbi.nlm.nih.gov/pubmed/37641687
http://dx.doi.org/10.2147/CMAR.S353374

Ejemplares similares